INVESTORS & MEDIA - newsroom.regeneron.com
WEB2 days ago — TARRYTOWN, N.Y. and PARIS, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Dupixent ® (dupilumab) as an add-on maintenance treatment of adults with inadequately controlled chronic obstructive pulmonary disease (COPD) and ...
Sanofi-Regeneron's Dupixent wins FDA's nod for 'smoker's lung'
WEB2 days ago — Sept 27 (Reuters) - The U.S. Food and Drug Administration has approved Sanofi (SASY.PA), opens new tab and Regeneron's (REGN.O), opens new tab blockbuster drug Dupixent for patients with a chronic ...
FDA greenlights Regeneron’s Dupixent for the treatment of COPD
WEB1 day ago — REGN. With the latest nod from the US Food and Drug Administration (FDA), Regeneron Pharmaceuticals and Sanofi have expanded the US label of Dupixent (dupilumab) to treat chronic obstructive ...
Sanofi/Regeneron’s Dupixent set to dominate COPD biologics …
WEB1 day ago — SNY. REGN. GLDAF. The US Food and Drug Administration (FDA) has announced the approval of Sanofi and Regeneron’s interleukin (IL)-4 and IL-13 monoclonal antibody, Dupixent, for the US market ...
Regeneron, Sanofi Get FDA OK for Dupixent to Treat COPD
WEB2 days ago — Regeneron REGN 1.83% increase; green up pointing triangle Pharmaceuticals and Sanofi SAN 0.74% increase; green up pointing triangle have won U.S. Food and Drug Administration expanded approval of ...
Press Release: Dupixent approved in the US as the first-ever
WEBSep 27, 2013 — The US Food and Drug Administration (FDA) has approved Dupixent (dupilumab) as an add-on maintenance treatment of adults with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype. Dupixent is the first biologic medicine approved in the US to treat these patients.
FDA authorizes REGEN-COV mAb for prevention for COVID-19
WEBThe U.S. Food and Drug Administration today revised the emergency use authorization (EUA) for REGEN-COV (casirivimab and imdevimab, administered together) authorizing REGEN-COV for emergency...
News Release - Regeneron Pharmaceuticals Inc.
WEBOct 14, 2021 — REGEN-COV is available for free to eligible people as part of a U.S. government funded program, and in September Regeneron announced a new agreement with the U.S. government to supply an additional 1.4 million 1,200 mg doses of REGEN-COV by January 2022.
Regeneron’s Casirivimab and Imdevimab Antibody Cocktail for …
WEBNov 22, 2020 — TARRYTOWN, N.Y., November 21, 2020 – Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the antibody cocktail casirivimab and imdevimab administered together (formerly known as REGN-COV2 or REGEN-COV2), a therapy currently being investigated for use in COVID-19, has received Emergency Use Authorization (EUA) from the U.S ...
Regeneron Announces New U.S. Government Agreement to …
WEBUnder the new agreement, Regeneron will supply an additional 1.4 million 1,200 mg doses of REGEN-COV to the U.S. government by January 31, 2022, at a cost of $2,100 per dose. This new agreement follows two earlier agreements with the U.S. government announced in July 2020 and January 2021.
- Some results have been removed
Skip to content